Ovarian function, fertility and reproductive lifespan in cancer patients

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerbase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013 [updated 2012; cited 2017 Nov 28]. Available from: http://globocan.iarc.fr,
   Google Scholar
• van Dorp W, Mulder RL, Kremer LC, et al. Recommendations for premature ovarian insufficiency surveillance for female survivors of childhood, adolescent, and young adult cancer: a report from the international late effects of childhood cancer guideline harmonization group in collaboration with the PanCareSurFup consortium. JCO. 2016;34(28):3440–3450.
   PubMed Web of Science ®Google Scholar
• Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333–2344.
   PubMed Web of Science ®Google Scholar
• Crawshaw M. Psychosocial oncofertility issues faced by adolescents and young adults over their lifetime: a review of the research. Hum Fertil (Camb). 2013;16(1):59–63.
   PubMed Web of Science ®Google Scholar
• Lehmann V, Keim MC, Nahata L, et al. Fertility-related knowledge and reproductive goals in childhood cancer survivors: short communication. Hum Reprod. 2017;32(11):2250–2253.
   PubMed Web of Science ®Google Scholar
• Nilsson J, Jervaeus A, Lampic C, et al. ‘Will I be able to have a baby?’ Results from online focus group discussions with childhood cancer survivors in Sweden. Hum Reprod. 2014;29(12):2704–2711.
   PubMed Web of Science ®Google Scholar
• Letourneau JM, Ebbel EE, Katz PP, et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer. 2012;118(7):1933–1939.
   PubMed Web of Science ®Google Scholar
• Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA. 2017;318(14):1367–1376.
   PubMed Web of Science ®Google Scholar
• Findlay JK, Hutt KJ, Hickey M, et al. How is the number of primordial follicles in the ovarian reserve established? Biol Reprod. 2015 Nov;93(5):111.
   PubMed Web of Science ®Google Scholar
• Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PloS One. 2010;5(1):e8772.
   PubMed Web of Science ®Google Scholar
• Peters H, Byskov AG, Grinsted J. Follicular growth in fetal and prepubertal ovaries of humans and other primates. Clin Endocrinol Metab. 1978;7(3):469–485.
   PubMedGoogle Scholar
• Zuccotti M, Merico V, Cecconi S, et al. What does it take to make a developmentally competent mammalian egg? Hum Reprod Update. 2011;17(4):525–540.
   PubMed Web of Science ®Google Scholar
• van Noord PA, Dubas JS, Dorland M, et al. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril. 1997;68(1):95–102.
   PubMed Web of Science ®Google Scholar
• Tucker EJ, Grover SR, Bachelot A, et al. Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic spectrum. Endocr Rev. 2016;37(6):609–635.
   PubMed Web of Science ®Google Scholar
• Kok HS, van Asselt KM, van der Schouw YT, et al. Genetic studies to identify genes underlying menopausal age. Hum Reprod Update. 2005;11(5):483–493.
   PubMed Web of Science ®Google Scholar
• Reddy P, Zheng W, Liu K. Mechanisms maintaining the dormancy and survival of mammalian primordial follicles. Trends Endocrinol Metab. 2010;21(2):96–103.
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Gruijters MJ, Kramer P, et al. Anti-mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. 2002;143(3):1076–1084.
   PubMed Web of Science ®Google Scholar
• Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol Hum Reprod. 2013;19(8):519–527.
   PubMed Web of Science ®Google Scholar
• de Vet A, Laven JS, de Jong FH, et al. Antimullerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357–362.
   PubMed Web of Science ®Google Scholar
• Kelsey TW, Wright P, Nelson SM, et al. A validated model of serum anti-mullerian hormone from conception to menopause. PloS One. 2011;6(7):e22024.
   PubMed Web of Science ®Google Scholar
• Hagen CP, Aksglaede L, Sorensen K, et al. Individual serum levels of anti-mullerian hormone in healthy girls persist through childhood and adolescence: a longitudinal cohort study. Hum Reprod. 2012;27(3):861–866.
   PubMed Web of Science ®Google Scholar
• Jeffery A, Streeter AJ, Hosking J, et al. Anti-mullerian hormone in children: a ten-year prospective longitudinal study (EarlyBird 39). J Pediatr Endocrinol Metab. 2015;28(9–10):1153–1162.
   PubMed Web of Science ®Google Scholar
• Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478–3483.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Mansi J, Coleman RE, et al. The utility of anti-mullerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2017 Dec;87:58–64.
   PubMed Web of Science ®Google Scholar
• Anderson RA, McLaughlin M, Wallace WH, et al. The immature human ovary shows loss of abnormal follicles and increasing follicle developmental competence through childhood and adolescence. Hum Reprod. 2014;29(1):97–106.
   PubMed Web of Science ®Google Scholar
• Kano M, Sosulski AE, Zhang L, et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci USA. 2017;114(9):E1688–E1697.
   PubMed Web of Science ®Google Scholar
• Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary? Hum Reprod Update. 2012;18(5):525–535.
   PubMed Web of Science ®Google Scholar
• Wallace WH, Thomson AB, Saran F, et al. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005;62(3):738–744.
   PubMed Web of Science ®Google Scholar
• Teh WT, Stern C, Chander S, et al. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014;2014:482968.
   PubMed Web of Science ®Google Scholar
• Chemaitilly W, Li Z, Krasin MJ, et al. Premature ovarian insufficiency in childhood cancer survivors: a report from the St. Jude Lifetime Cohort. J Clin Endocrinol Metab. 2017;102(7):2242–2250.
   PubMed Web of Science ®Google Scholar
• Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol. 1999;106(12):1265–1272.
   PubMedGoogle Scholar
• Signorello LB, Cohen SS, Bosetti C, et al. Female survivors of childhood cancer: preterm birth and low birth weight among their children. J Natl Cancer Inst. 2006;98(20):1453–1461.
   PubMedGoogle Scholar
• Signorello LB, Mulvihill JJ, Green DM, et al. Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. Lancet. 2010 21;376(9741):624–630.
   PubMed Web of Science ®Google Scholar
• Salooja N, Szydlo RM, Socie G, et al. Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey. Lancet. 2001;358(9278):271–276.
   PubMed Web of Science ®Google Scholar
• Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res. 2007;67(21):10159–10162.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Rosendahl M, Kelsey TW, et al. Pretreatment anti-mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer. 2013;49(16):3404–3411.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Themmen AP, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006;21(10):2583–2592.
   PubMed Web of Science ®Google Scholar
• Rosendahl M, Andersen CY, la Cour Freiesleben N, et al. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril. 2010;94(1):156–166.
   PubMed Web of Science ®Google Scholar
• Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimullerian hormone levels determine rate of post-therapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99(2):477–483.
   PubMed Web of Science ®Google Scholar
• Oktay K, Turan V, Titus S, et al. BRCA mutations, DNA repair deficiency, and ovarian aging. Biol Reprod. 2015;93(3):67.
   PubMed Web of Science ®Google Scholar
• Kalich-Philosoph L, Roness H, Carmely A, et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):185ra62.
   PubMed Web of Science ®Google Scholar
• Adhikari D, Liu K. Molecular mechanisms underlying the activation of mammalian primordial follicles. Endocr Rev. 2009;30(5):438–464.
   PubMed Web of Science ®Google Scholar
• Soleimani R, Heytens E, Darzynkiewicz Z, et al. Mechanisms of chemotherapy-induced human ovarian aging: double strand DNA breaks and microvascular compromise. Aging (Albany NY). 2011;3(8):782–793.
   PubMedGoogle Scholar
• Meirow D, Dor J, Kaufman B, et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22(6):1626–1633.
   PubMed Web of Science ®Google Scholar
• Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. JCO. 2006 1;24(7):1045–1051.
   PubMed Web of Science ®Google Scholar
• Vriens IJ, De Bie AJ, Aarts MJ, et al. The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients. Oncotarget. 2017;8(7):11372–11379.
   PubMedGoogle Scholar
• Wu X, Cai H, Kallianpur A, et al. Impact of premature ovarian failure on mortality and morbidity among Chinese women. PloS One. 2014;9(3):e89597.
   PubMed Web of Science ®Google Scholar
• Marino JL, Saunders CM, Hickey M. Sexual inactivity in partnered female cancer survivors. Maturitas. 2017;105:89–94.
   PubMed Web of Science ®Google Scholar
• Faubion SS, Sood R, Kapoor E. Genitourinary syndrome of menopause: management strategies for the clinician. Mayo Clin Proc. 2017;92(12):1842–1849.
   PubMed Web of Science ®Google Scholar
• Vearncombe KJ, Pachana NA. Is cognitive functioning detrimentally affected after early, induced menopause? Menopause. 2009;16(1):188–198.
   PubMed Web of Science ®Google Scholar
• European Society for Human Reproduction, Embryology Guideline Group on POI, Webber L, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926–937.
   PubMed Web of Science ®Google Scholar
• Mueller BA, Chow EJ, Kamineni A, et al. Pregnancy outcomes in female childhood and adolescent cancer survivors: a linked cancer-birth registry analysis. Arch Pediatr Adolesc Med. 2009;163(10):879–886.
   PubMedGoogle Scholar
• Signorello LB, Mulvihill JJ, Green DM, et al. Congenital anomalies in the children of cancer survivors: a report from the childhood cancer survivor study. JCO. 2012;30(3):239–245.
   PubMed Web of Science ®Google Scholar
• Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91(5):1723–1728.
   PubMed Web of Science ®Google Scholar
• Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309(22):2371–2381.
   PubMed Web of Science ®Google Scholar
• Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2013;14(9):873–881.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Cooke R, Bates A, et al. Risk of premature menopause after treatment for Hodgkin’s lymphoma. J Natl Cancer Inst. 2014;106(9). DOI:10.1093/jnci/dju207
   Google Scholar
• Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol. 2007;30(2):126–132.
   PubMed Web of Science ®Google Scholar
• Okanami Y, Ito Y, Watanabe C, et al. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182–188.
   PubMed Web of Science ®Google Scholar
• Loren AW. Fertility issues in patients with hematologic malignancies. Hematology Am Soc Hematol Educ Program. 2015;2015:138–145.
   PubMedGoogle Scholar
• Chow EJ, Stratton KL, Leisenring WM, et al. Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2016;17(5):567–576.
   PubMed Web of Science ®Google Scholar
• Tauchmanova L, Selleri C, De Rosa G, et al. Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. Hum Reprod. 2003;18(7):1410–1416.
   PubMed Web of Science ®Google Scholar
• Vatanen A, Wilhelmsson M, Borgstrom B, et al. Ovarian function after allogeneic hematopoietic stem cell transplantation in childhood and adolescence. Eur J Endocrinol. 2014;170(2):211–218.
   PubMed Web of Science ®Google Scholar
• Bramswig JH, Riepenhausen M, Schellong G. Parenthood in adult female survivors treated for Hodgkin’s lymphoma during childhood and adolescence: a prospective, longitudinal study. Lancet Oncol. 2015;16(6):667–675.
   PubMed Web of Science ®Google Scholar
• Bath LE, Wallace WH, Shaw MP, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod. 2003;18(11):2368–2374.
   PubMed Web of Science ®Google Scholar
• Wu KN, Luo Y, Liu LZ, et al. Twin pregnancy and childbirth after reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation combined with imatinib mesylate for chronic myeloid leukaemia: case report and literature review. J Int Med Res. 2012;40(6):2409–2415.
   PubMed Web of Science ®Google Scholar
• Phelan R, Mann E, Napurski C, et al. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning. Bone Marrow Transplant. 2016;51(10):1369–1375.
   PubMed Web of Science ®Google Scholar
• Jang H, Lee OH, Lee Y, et al. Melatonin prevents cisplatin-induced primordial follicle loss via suppression of PTEN/AKT/FOXO3a pathway activation in the mouse ovary. J Pineal Res. 2016;60(3):336–347.
   PubMed Web of Science ®Google Scholar
• Imai A, Ichigo S, Matsunami K, et al. Ovarian function following targeted anti-angiogenic therapy with bevacizumab. Mol Clin Oncol. 2017;6(6):807–810.
   PubMed Web of Science ®Google Scholar
• Zamah AM, Mauro MJ, Druker BJ, et al. Will imatinib compromise reproductive capacity? Oncologist. 2011;16(10):1422–1427.
   PubMed Web of Science ®Google Scholar
• Gonfloni S, Di Tella L, Caldarola S, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nature Medicine. 2009;15(10):1179–1185.
   PubMed Web of Science ®Google Scholar
• Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Annal Oncol. 2015;26(12):2408–2419.
   PubMed Web of Science ®Google Scholar
• Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. NEJM. 2015;372(10):923–932.
   PubMed Web of Science ®Google Scholar
• Leonard RCF, Adamson DJA, Bertelli G, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial. Annal Oncol. 2017;28(8):1811–1816.
   PubMed Web of Science ®Google Scholar
• Demeestere I, Brice P, Peccatori FA, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. JCO. 2016;34(22):2568–2574.
   PubMed Web of Science ®Google Scholar
• Kim SY, Kim SK, Lee JR, et al. Toward precision medicine for preserving fertility in cancer patients: existing and emerging fertility preservation options for women. J Gynecol Oncol. 2016;27(2):e22.
   PubMed Web of Science ®Google Scholar
• Tarlatzis BC, Zepiridis L. Perimenopausal conception. Ann NY Acad Sci. 2003;997:93–104.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metabolism. 2011;96(5):1336–1343.
   PubMed Web of Science ®Google Scholar
• Hagen CP, Vestergaard S, Juul A, et al. Low concentration of circulating antimullerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril. 2012;98(6):1602–8 e2.
   PubMed Web of Science ®Google Scholar
• Iliodromiti S, Kelsey TW, Wu O, et al. The predictive accuracy of anti-Mullerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update. 2014;20(4):560–570.
   PubMed Web of Science ®Google Scholar
• Torino F, Barnabei A, De Vecchis L, et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol. 2014;89(1):27–42.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717.
   PubMed Web of Science ®Google Scholar
• Regan MM, Francis PA, Pagani O, et al. Absolute benefit of adjuvant endocrine therapies for premenopausal womenwith hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials. JCO. 2016;34(19):2221–2231.
   PubMed Web of Science ®Google Scholar
• Buzdar AU. Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clin Cancer Res. 2003;9(1 Pt 2):468S–72S.
   PubMed Web of Science ®Google Scholar
• Guerrero A, Gavila J, Folkerd E, et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Annal Oncol. 2013;24(3):674–679.
   PubMed Web of Science ®Google Scholar
• Krekow LK, Hellerstedt BA, Collea RP, et al. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. JCO. 2016 10;34(14):1594–1600.
   PubMed Web of Science ®Google Scholar
• Anderson RA, Nelson SM, Wallace WH. Measuring anti-mullerian hormone for the assessment of ovarian reserve: when and for whom is it indicated? Maturitas. 2012;71(1):28–33.
   PubMed Web of Science ®Google Scholar
• Chai J, Howie AF, Cameron DA, et al. A highly-sensitive anti-mullerian hormone assay improves analysis of ovarian function following chemotherapy for early breast cancer. Eur J Cancer. 2014;50(14):2367–2374.
   PubMed Web of Science ®Google Scholar
• Kelsey TW, Dodwell SK, Wilkinson AG, et al. Ovarian volume throughout life: a validated normative model. PloS One. 2013;8(9):e71465.
   PubMed Web of Science ®Google Scholar
• Kelsey TW, Wallace WH. Ovarian volume correlates strongly with the number of nongrowing follicles in the human ovary. Obstet Gynecol Int. 2012;2012:305025.
   PubMedGoogle Scholar
• McLaughlin M, Kelsey TW, Wallace WH, et al. An externally validated age-related model of mean follicle density in the cortex of the human ovary. J Assist Reprod Genet. 2015;32(7):1089–1095.
   PubMed Web of Science ®Google Scholar
• Wenners A, Grambach J, Koss J, et al. Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial. BMC Cancer. 2017 6;17(1):632.
   PubMedGoogle Scholar
• Iliodromiti S, Anderson RA, Nelson SM. Technical and performance characteristics of anti-Mullerian hormone and antral follicle count as biomarkers of ovarian response. Hum Reprod Update. 2015;21(6):698–710.
   PubMed Web of Science ®Google Scholar
• Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):685–718.
   PubMed Web of Science ®Google Scholar
• Broer SL, Dolleman M, Opmeer BC, et al. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011;17(1):46–54.
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sammel MD, Lin H, et al. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab. 2012;97(5):1673–1680.
   PubMed Web of Science ®Google Scholar
• La Marca A, Malmusi S, Giulini S, et al. Anti-mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod. 2004;19(12):2738–2741.
   PubMed Web of Science ®Google Scholar
• Kissell KA, Danaher MR, Schisterman EF, et al. Biological variability in serum anti-mullerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women. Hum Reprod. 2014;29(8):1764–1772.
   PubMed Web of Science ®Google Scholar
• Bungum L, Jacobsson AK, Rosen F, et al. Circadian variation in concentration of anti-mullerian hormone in regularly menstruating females: relation to age, gonadotrophin and sex steroid levels. Hum Reprod. 2011;26(3):678–684.
   PubMed Web of Science ®Google Scholar
• Johnson LN, Sammel MD, Dillon KE, et al. Antimullerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception. Fertil Steril. 2014 Sep;102(3):774–781.
   PubMed Web of Science ®Google Scholar
• Phillips KA, Collins IM, Milne RL, et al. Anti-Mullerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126–1132.
   PubMed Web of Science ®Google Scholar
• Lauritsen MP, Bentzen JG, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone. Hum Reprod. 2014;29(4):791–801.
   PubMed Web of Science ®Google Scholar
• Lawrenz B, Fehm T, von Wolff M, et al. Reduced pretreatment ovarian reserve in premenopausal female patients with Hodgkin lymphoma or non-Hodgkin-lymphoma–evaluation by using antimullerian hormone and retrieved oocytes. Fertil Steril. 2012;98(1):141–144.
   PubMed Web of Science ®Google Scholar
• Freeman EW, Sammel MD, Lin H, et al. Contribution of the rate of change of antimullerian hormone in estimating time to menopause for late reproductive-age women. Fertil Steril. 2012;98(5):1254–1259.
   PubMed Web of Science ®Google Scholar
• Visser JA, Schipper I, Laven JS, et al. Anti-mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8(6):331–341.
   PubMed Web of Science ®Google Scholar
• Brodin T, Hadziosmanovic N, Berglund L, et al. Antimullerian hormone levels are strongly associated with live-birth rates after assisted reproduction. J Clin Endocrinol Metab. 2013;98(3):1107–1114.
   PubMed Web of Science ®Google Scholar
• Arce JC, La Marca A, Mirner Klein B, et al. Antimullerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients. Fertil Steril. 2013;99(6):1644–1653.
   PubMed Web of Science ®Google Scholar
• Wu CH, Chen YC, Wu HH, et al. Serum anti-mullerian hormone predicts ovarian response and cycle outcome in IVF patients. J Assist Reprod Genet. 2009;26(7):383–389.
   PubMed Web of Science ®Google Scholar
• Su HI, Sammel MD, Green J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010;116(3):592–599.
   PubMed Web of Science ®Google Scholar
• Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010;94(2):638–644.
   PubMed Web of Science ®Google Scholar
• Decanter C, Morschhauser F, Pigny P, et al. Anti-mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010;20(2):280–285.
   PubMed Web of Science ®Google Scholar
• Dunlop CE, Brady BM, McLaughlin M, et al. Re-implantation of cryopreserved ovarian cortex resulting in restoration of ovarian function, natural conception and successful pregnancy after haematopoietic stem cell transplantation for Wilms tumour. J Assist REprod Genet. 2016 Dec;33(12):1615–1620.
   PubMed Web of Science ®Google Scholar
• Gupta AA, Lee Chong A, Deveault C, et al. Anti-mullerian hormone in female adolescent cancer patients before, during, and after completion of therapy: a pilot feasibility study. J Ped Adolesc Gynecol. 2016;29(6):599–603.
   PubMed Web of Science ®Google Scholar
• Brougham MF, Crofton PM, Johnson EJ, et al. Anti-Mullerian hormone is a marker of gonadotoxicity in pre- and postpubertal girls treated for cancer: a prospective study. J Clin Endocrinol Metab. 2012;97(6):2059–2067.
   PubMed Web of Science ®Google Scholar
• Miyoshi Y, Ohta H, Namba N, et al. Low serum concentrations of anti-mullerian hormone are common in 53 female childhood cancer survivors. Horm Res Paediatr. 2013;79(1):17–21.
   PubMed Web of Science ®Google Scholar
• Li XS, Lv Q, Du ZG, et al. Prediction of ovarian function in premenopausal breast cancer patients with amenorrhoea after chemotherapy: a simple clinical score. Springerplus. 2016;5(1):1052.
   PubMedGoogle Scholar
• D’Avila AM, Biolchi V, Capp E, et al. Age, anti-mullerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide. J Ovarian Res. 2015;8(14):82.
   PubMed Web of Science ®Google Scholar
• Su HC, Haunschild C, Chung K, et al. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014 1;120(23):3691–3698.
   PubMed Web of Science ®Google Scholar
• Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. NEJM. 2001;344(26):1997–2008.
   PubMed Web of Science ®Google Scholar
• Ruddy KJ, O’Neill A, Miller KD, et al. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014;144(3):591–597.
   PubMed Web of Science ®Google Scholar
• Henry NL, Xia R, Schott AF, et al. Prediction of postchemotherapy ovarian function using markers of ovarian reserve. Oncologist. 2014;19(1):68–74.
   PubMed Web of Science ®Google Scholar
• Anders C, Marcom PK, Peterson B, et al. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer. Cancer Invest. 2008;26(3):286–295.
   PubMed Web of Science ®Google Scholar
• Peigne M, Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review. Reprod Biol Endocrinol. 2014;12:26.
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Births by parents’ characteristics in England and Wales: 2016. 2017.
   Google Scholar
• Nelson SM, Telfer EE, Anderson RA. The ageing ovary and uterus: new biological insights. Human Reprod Update. 2013;19(1):67–83.
   Google Scholar